SEGMENT INFORMATION (Tables)

12 Months Ended

Oct. 31, 2021

Segment Reporting [Abstract]

SCHEDULE OF SEGMENT INFORMATION

	Year Ended October 31,
	2021			2020
Net income/(loss):
CAR-T Therapeutics	$	(5,672,622	)	$	(2,241,443	)
Cancer Vaccines		(4,558,811	)		(828,136	)
Anti-Viral Therapeutics		(2,927,979	)		(1,168,969	)
Cancer Diagnostics		(78,067	)		(5,836,594	)
Patent Licensing		109,556			(17,221	)
Total	$	(13,127,923	)	$	(10,092,363	)
Total operating costs and expenses	$	13,648,192		$	9,978,202
Less non-cash share-based compensation		(8,058,078	)		(4,137,460	)
Operating costs and expenses excluding non-cash share-based compensation	$	5,590,114		$	5,840,742
Operating costs and expenses excluding non-cash share based compensation:
CAR-T Therapeutics	$	2,421,487		$	1,141,542
Cancer Vaccines		1,641,977			365,681
Anti-Viral Therapeutics		1,080,279			739,140
Cancer Diagnostics		49,170			3,581,377
Patent Licensing		397,201			13,002
Total	$	5,590,114		$	5,840,742

	October 31,
	2021		2020
Total assets:
CAR-T Therapeutics	$	15,067,933	$	2,988,124
Cancer Vaccines		13,276,518		946,923
Anti-Viral Therapeutics		7,368,214		2,464,361
Cancer Diagnostics		391,618		2,869,529
Patent Licensing		153,121		184,027
Total	$	36,257,404	$	9,452,964